Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

Authors

Rina Hui

Westmead Hospital and the University of Sydney, Sydney, NSW, Australia

Rina Hui , Makoto Nishio , Martin Reck , Delvys Rodriguez-Abreu , Tamer M. Fouad , Doreen Flaim , Lina Yin , Thao Dang , Roy S. Herbst

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

First Author: Marina Chiara Garassino

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non–small cell lung carcinoma (NSCLC): KEYNOTE-189.

First Author: Richard Delmar Hall

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).

First Author: Edward B. Garon

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.

First Author: Salma K. Jabbour